J. Mamza

First name
J.
Middle name
B.
Last name
Mamza
Mizani, M. A., Dashtban, A., Pasea, L., Zeng, Q., Khunti, K., Valabhji, J., et al. (2024). Identifying subtypes of type 2 diabetes mellitus with machine learning: development, internal validation, prognostic validation and medication burden in linked electronic health records in 420 448 individuals. Bmj Open Diabetes Res Care, 12. http://doi.org/10.1136/bmjdrc-2024-004191
Dashtban, A., Mizani, M. A., Pasea, L., Denaxas, S., Corbett, R., Mamza, J. B., et al. (2023). Identifying subtypes of chronic kidney disease with machine learning: development, internal validation and prognostic validation using linked electronic health records in 350,067 individuals. Ebiomedicine, 89, 104489. http://doi.org/10.1016/j.ebiom.2023.104489
Mizani, M. A., Dashtban, A., Pasea, L., Lai, A. G., Thygesen, J., Tomlinson, C., et al. (2022). Using national electronic health records for pandemic preparedness: validation of a parsimonious model for predicting excess deaths among those with COVID-19-a data-driven retrospective cohort study. J R Soc Med, 1410768221131897. http://doi.org/10.1177/01410768221131897
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2021). Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease. Diabetes Obes Metab, 23, 2207-2214. http://doi.org/10.1111/dom.14437
Birkeland, K. I., Bodegard, J., Banerjee, A., Kim, D. J., Norhammar, A., Eriksson, J. W., et al. (2021). Lower cardiorenal risk with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study. Diabetes Obes Metab, 23, 75-85. http://doi.org/10.1111/dom.14189
Idris, I., Zhang, R., Mamza, J. B., Ford, M., Morris, T., Banerjee, A., & Khunti, K. (2022). Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting. Diabetes Obes Metab. http://doi.org/10.1111/dom.14799
Dashtban, A., Mizani, M. A., Denaxas, S., Nitsch, D., Quint, J., Corbett, R., et al. (2022). A retrospective cohort study measured predicting and validating the impact of the COVID-19 pandemic in individuals with chronic kidney disease. Kidney Int. http://doi.org/10.1016/j.kint.2022.05.015
Gurol-Urganci, I., Geary, R. S., Mamza, J. B., Iwagami, M., El-Hamamsy, D., Duckett, J., et al. (2020). Determinants of referral of women with urinary incontinence to specialist services: a national cohort study using primary care data from the UK. BMC Fam Pract. http://doi.org/10.1186/s12875-020-01282-y